IN189732B - - Google Patents

Info

Publication number
IN189732B
IN189732B IN616DE1998A IN189732B IN 189732 B IN189732 B IN 189732B IN 616DE1998 A IN616DE1998 A IN 616DE1998A IN 189732 B IN189732 B IN 189732B
Authority
IN
India
Prior art keywords
cell lines
desired dna
mammalian cell
mammalian
site
Prior art date
Application number
Other languages
English (en)
Inventor
Mitchell Elliot Reff
Richard Spence Barnett
Karen Retta Mclachlan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26697516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN189732(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/819,866 external-priority patent/US5830698A/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of IN189732B publication Critical patent/IN189732B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN616DE1998 1997-03-14 1998-03-10 IN189732B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/819,866 US5830698A (en) 1997-03-14 1997-03-14 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US09/023,715 US5998144A (en) 1997-03-14 1998-02-13 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Publications (1)

Publication Number Publication Date
IN189732B true IN189732B (de) 2003-04-19

Family

ID=26697516

Family Applications (1)

Application Number Title Priority Date Filing Date
IN616DE1998 IN189732B (de) 1997-03-14 1998-03-10

Country Status (21)

Country Link
US (3) US6413777B1 (de)
EP (1) EP0981637B1 (de)
JP (1) JP4128227B2 (de)
CN (1) CN1175111C (de)
AT (1) ATE296356T1 (de)
AU (1) AU737155B2 (de)
BR (1) BR9808584A (de)
CA (1) CA2283740C (de)
CZ (1) CZ293355B6 (de)
DE (1) DE69830312T2 (de)
ES (1) ES2242997T3 (de)
ID (1) ID24565A (de)
IL (1) IL131746A0 (de)
IN (1) IN189732B (de)
NO (1) NO994397L (de)
PL (1) PL191251B1 (de)
PT (1) PT981637E (de)
RO (1) RO120148B1 (de)
RU (1) RU2004107694A (de)
TW (1) TWI232239B (de)
WO (1) WO1998041645A1 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
BR9808584A (pt) * 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
AU746786B2 (en) 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
AU2400500A (en) * 1999-11-01 2001-05-14 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
CN1322138C (zh) * 2000-06-23 2007-06-20 诺维信公司 用于基因的稳定的染色体多拷贝整合的方法
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
DE60230918D1 (de) 2001-11-16 2009-03-05 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
US7164056B2 (en) * 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
EP2314629B2 (de) 2002-07-18 2022-11-16 Merus N.V. Rekombinante Herstellung von Mischungen aus Aantikörpern
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004042007A2 (en) * 2002-10-30 2004-05-21 University Of Iowa Research Foundation Somatic cell gene targeting vectors and methods of use thereof
CA2512647C (en) * 2003-01-07 2013-10-08 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
US9856484B2 (en) * 2003-01-31 2018-01-02 Bayer Cropscience N.V. Plant transformation with in vivo assembly of a trait
DE10303937A1 (de) * 2003-01-31 2004-08-12 Icon Genetics Ag Pflanzentransformation mit Assemblierung einer gewünschten Sequenz in Vivo
PL2248899T3 (pl) * 2003-03-19 2015-10-30 Biogen Ma Inc Białko wiążące receptor nogo
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
CA2536807C (en) * 2003-09-04 2010-07-13 Medarex, Inc. Expression vector
US7344753B2 (en) * 2003-09-19 2008-03-18 The Board Of Trustees Of The University Of Illinois Nanostructures including a metal
US8030833B2 (en) * 2003-09-19 2011-10-04 The Board Of Trustees Of The University Of Illinois Electron emission device incorporating free standing monocrystalline nanowires
US7935862B2 (en) * 2003-12-02 2011-05-03 Syngenta Participations Ag Targeted integration and stacking of DNA through homologous recombination
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
PL1787126T3 (pl) 2004-07-20 2010-03-31 Symphogen As Sposób charakteryzowania poliklonalnej linii komórkowej
WO2006017673A2 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
AU2006203889A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. CRIPTO binding molecules
CN100381573C (zh) * 2005-04-14 2008-04-16 北京天广实生物技术有限公司 快速构建目标基因高表达的哺乳动物细胞株的体系和方法
CA2902070A1 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20090186097A1 (en) * 2005-08-09 2009-07-23 David Lee Ayares Transgenic Ungulates Expressing CTLA4-IG and Uses Thereof
WO2007056161A1 (en) 2005-11-04 2007-05-18 Biogen Idec Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
EP1965827B1 (de) 2005-12-02 2015-02-25 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
CA2640423C (en) 2006-01-27 2016-03-15 Biogen Idec Ma Inc. Nogo receptor antagonists
PT2099826E (pt) 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
CN101636168B (zh) 2007-01-09 2013-05-29 比奥根艾迪克Ma公司 Sp35抗体及其用途
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
NZ578816A (en) 2007-02-02 2012-06-29 Biogen Idec Inc Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
CN101918540B (zh) * 2007-11-08 2016-05-11 比奥根Ma公司 Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
AU2008335178A1 (en) * 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
EP2382238A1 (de) 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anti-lymphotoxin-antik?rper
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
US20120270264A1 (en) 2009-10-01 2012-10-25 Toto Ltd. Dna construct, and process for production of recombinant cho cell using same
PL3251503T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
SG184903A1 (en) * 2010-04-30 2012-11-29 Temasek Life Sciences Lab Ltd Fragment switch: a reverse genetic approach
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
DK2640743T3 (en) 2010-11-16 2017-01-23 Excelimmune Inc PROCEDURES FOR THE PREPARATION OF RECOMBINANT PROTEINS
JP5209693B2 (ja) * 2010-12-10 2013-06-12 ロンザ・バイオロジクス・ピーエルシー Ｃｈｏ細胞において組換えタンパク質を発現する方法
JP6067575B2 (ja) 2010-12-17 2017-01-25 ニューリミューン ホールディング エイジー ヒト抗ｓｏｄ１抗体
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
RU2645475C2 (ru) 2012-04-25 2018-02-21 Регенерон Фармасьютикалз, Инк. Опосредованное нуклеазой нацеливание с большими нацеливающими векторами
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
EP2863940A4 (de) 2012-06-08 2016-08-10 Biogen Ma Inc Chimäre gerinnungsfaktoren
CN104870014A (zh) 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
HRP20201422T1 (hr) 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
CN104936980B (zh) 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
CN107074937B (zh) 2014-07-29 2021-07-27 神经免疫控股公司 人源抗亨廷顿蛋白(htt)抗体及其用途
NZ729808A (en) 2014-09-30 2022-02-25 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN106191040B (zh) * 2015-04-30 2021-09-14 杭州菁因康生物科技有限公司 基因打靶方法
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
KR20180118659A (ko) 2016-02-01 2018-10-31 바이오버라티브 테라퓨틱스 인크. 최적화된 viii 인자 유전자
WO2017214376A1 (en) 2016-06-10 2017-12-14 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US20200031924A1 (en) 2016-07-13 2020-01-30 Biogen Ma Inc. Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
BR112020002394A2 (pt) 2017-08-09 2020-07-28 Bioverativ Therapeutics Inc. moléculas de ácidos nucleicos e usos das mesmas
KR102824112B1 (ko) 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
KR20210018807A (ko) 2018-04-27 2021-02-18 바이오젠 엠에이 인코포레이티드 인간-유래 항-(폴리-ga) 디펩타이드 반복 (dpr) 항체
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
CN110607326B (zh) * 2018-06-15 2022-11-29 江苏省农业科学院 非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用
KR102925832B1 (ko) 2018-08-09 2026-02-11 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
US20220049275A1 (en) * 2018-10-01 2022-02-17 Lonza, Ltd. Ssi cells with predictable and stable transgene expression and methods of formation
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
JP7588080B2 (ja) 2019-02-13 2024-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 抗末梢リンパ節アドレッシン抗体およびその使用
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
JP2023516028A (ja) 2020-02-28 2023-04-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 多重特異性抗体を介したトランスフォーミング増殖因子ベータスーパーファミリーシグナル伝達の選択的調節
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
IL310997A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
AR126845A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Producción de adn de extremo cerrado con secuencias repetidas de terminal invertida
EP4408874A1 (de) 2021-09-30 2024-08-07 Bioverativ Therapeutics Inc. Faktor viii polypeptid kodierende nukleinsäuren mit verminderter immunogenität
TW202528347A (zh) 2023-11-15 2025-07-16 瑞士商紐立慕公司 抗運甲狀腺素蛋白抗體、包含所述抗體之組成物及用於治療或預防運甲狀腺素蛋白介導之澱粉樣變性的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
AU4401993A (en) * 1992-06-04 1993-12-30 Exemplar Corporation Insertion of heterologous dna outside of known chromosomal genes
MX9305183A (es) * 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same

Also Published As

Publication number Publication date
BR9808584A (pt) 2000-05-23
AU737155B2 (en) 2001-08-09
US20040166528A1 (en) 2004-08-26
ID24565A (id) 2000-07-27
NO994397D0 (no) 1999-09-10
PL191251B1 (pl) 2006-04-28
ES2242997T3 (es) 2005-11-16
CN1175111C (zh) 2004-11-10
NO994397L (no) 1999-11-09
CN1255166A (zh) 2000-05-31
PL335695A1 (en) 2000-05-08
US7235360B2 (en) 2007-06-26
AU6443598A (en) 1998-10-12
ATE296356T1 (de) 2005-06-15
US20020192820A1 (en) 2002-12-19
JP4128227B2 (ja) 2008-07-30
PT981637E (pt) 2005-09-30
EP0981637B1 (de) 2005-05-25
CZ293355B6 (cs) 2004-04-14
RO120148B1 (ro) 2005-09-30
IL131746A0 (en) 2001-03-19
CA2283740C (en) 2006-06-27
JP2001516221A (ja) 2001-09-25
CZ316299A3 (cs) 2000-02-16
EP0981637A1 (de) 2000-03-01
DE69830312T2 (de) 2006-02-02
WO1998041645A1 (en) 1998-09-24
DE69830312D1 (de) 2005-06-30
US6841383B2 (en) 2005-01-11
TWI232239B (en) 2005-05-11
US6413777B1 (en) 2002-07-02
CA2283740A1 (en) 1998-09-24
RU2004107694A (ru) 2005-08-27

Similar Documents

Publication Publication Date Title
IL131746A0 (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
MY137837A (en) Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
DK1097211T3 (da) Ekspression af eukaryote peptider i planteplastider
ATE303448T1 (de) Duale selektionkassette und sie enthaltende plasmide
IL193758A0 (en) Genetically engineered duckweed
CA2234071A1 (en) Intensive homologous promoter obtained from hamsters
EP2278022A3 (de) Expressionsvektoren, Transfektionssysteme und Verfahren zu deren Verwendung
CA2203569A1 (en) Nucleotide sequence encoding the enzyme i-scei and the uses thereof
MX9709317A (es) Cromosomas sinteticos de mamifero y metodos para su construccion.
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU5659898A (en) Gene-trapping construct for the identification and isolation of genes
ATE244311T1 (de) Expressionssystem von antikörpern bei homologischer rekombinierung in murinezellen
DE69923983D1 (de) Expressionsvektoren die 'hot spots'für eine verstärkte rekombinante proteinexpression in transfizierten zellen enthalten
NO892029L (no) Fremgangsmaate ved spesifikk genetisk manipulering av mikroorganisme.
SE8101665L (sv) Polypeptidframstellning
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
NZ296562A (en) Recombinant peptides and secretory mehods for their preparation
WO2001079512A3 (en) Vector and method for targeted replacement and disruption of an integrated dna sequence
WO1994016074A3 (en) High molecular weight b-cell growth factor: interleukin-14
ES8706825A1 (es) Un procedimiento para preparar un plasmido recombinante
EP0160190A3 (de) Genetische Expression von Somatostatin als Hybridpolypeptid
EP0258046A3 (de) Verfahren zur Selektion von Rekombinante-DNS enthaltenden Streptomyceten und andere Wirtszellen
WO2000037682A8 (en) Method for augmenting expression of a foreign gene
WO2001081545A3 (en) Regulation of gene expression by hspbp1
CA2257867A1 (en) Editing-based selectable plastid marker genes